Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Recent developments at Seattle Genetics

Feb. 4, 2003

Phase I results for trastuzumab with IL-2 in nonhematological cancer

Feb. 4, 2003

AlphaRx acquires exclusive rights to VT-1

Jan. 30, 2003

Canvaxin receives fast track designation for metastatic melanoma

Jan. 29, 2003

HuMax-CD4 enters phase II clinical studies for CTCL

Jan. 28, 2003

Rights to cantuzumab mertansine returned to ImmunoGen

Jan. 28, 2003

Single-agent epratuzumab trial closes

Jan. 28, 2003

Pivotal OvaRex trials begin enrollment

Jan. 27, 2003

G17DT recommended for orphan drug status in E.U.

Jan. 24, 2003

New data on cantuzumab mertansine in tumors expressing the CanAg antigen

Jan. 22, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...